Lubrizol Unveils $60M Expansion Plan

Lubrizol LifeSciences is spending $60 million on new product solutions, capacity expansion and additional cGMP manufacturing, the company announced. It says these investments will bolster its excipients, polymers, drug formulation and manufacturing, and medical device contract manufacturing capabilities at Lubrizol LifeSciences’ global facilities.

Commercial drug product manufacturing will be added at the company’s Particle Sciences facility in Bethlehem, PA. Leveraging the company’s knowledge in complex formulations and production, the facility will be adjacent to the existing development and clinical trial manufacturing site, offering customers a seamless flow from development through manufacturing. This new space, which is expected to be operational in the fourth quarter of 2017, will accommodate both sterile and non-sterile products, highly potent compounds, and organic solvent processing.

Additionally, LifeSciences is investing to expand its global facilities for excipients, polymers and contract manufacturing, with a focus on quality and efficiency. This capital investment will impact multiple sites to increase in-house engineering capacity across the LifeSciences portfolio of medical and pharmaceutical applications. This includes new investments in design, manufacturing and sterilization technologies for the production of interventional catheters and long-term implantable devices, an area of strategic importance to the medical device segment.

"We have significantly enhanced our capabilities through the combination of strong polymer technology, application know-how and world-class manufacturing," said Deb Langer, vice president, Lubrizol Personal Home and Health Care. "As healthcare companies look for total solution providers, we continue to invest in the right areas to provide valuable offerings where our customers are experiencing the most growth."